DexCom, Inc. $DXCM Shares Purchased by Assetmark Inc.

Assetmark Inc. lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 161,368 shares of the medical device company’s stock after buying an additional 17,750 shares during the period. Assetmark Inc.’s holdings in DexCom were worth $10,134,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DXCM. Trust Co. of Vermont lifted its stake in shares of DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares during the period. CVA Family Office LLC increased its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares in the last quarter. V Square Quantitative Management LLC increased its position in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares in the last quarter. Essex Financial Services Inc. raised its stake in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after buying an additional 175 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in shares of DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 71,750 shares of company stock worth $5,163,241. 0.28% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DXCM. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price for the company in a research note on Tuesday, March 24th. TD Cowen restated a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a report on Wednesday, June 10th. Mizuho raised their price target on shares of DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Finally, UBS Group set a $95.00 price objective on DexCom in a research report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.36.

DexCom Stock Down 1.3%

Shares of DexCom stock opened at $75.69 on Tuesday. The stock has a market cap of $29.21 billion, a price-to-earnings ratio of 32.35, a price-to-earnings-growth ratio of 1.26 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a fifty day moving average price of $71.48 and a 200 day moving average price of $68.80.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. Equities research analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.